Datapoint: Regeneron’s Evkeeza Scores First-in-Class Approval for Ultra-Rare Heart Disease
The FDA on Feb. 11 approved Regeneron Pharmaceuticals, Inc.’s Evkeeza as an adjunct treatment to other low-density lipoprotein lowering therapies in patients 12 and older with homozygous familial hypercholestero...
Datapoint: Commonwealth Care Alliance to Expand Mass. Duals Demo
Boston-based community health org Commonwealth Care Alliance last week said it is expanding its One Care plan, a joint demonstration project with CMS that serves Medicare-Medicaid dual eligibles, into Berkshire Co...
Datapoint: Entresto Scores Expanded Heart Failure Label
The FDA last week approved a label expansion for Novartis’s Entresto, boosting its potential patient pool by millions of lives. The blockbuster drug is now approved for both heart failure with reduced ejection f...
Datapoint: Aetna to Rejoin ACA Exchange Markets
CVS Health CEO Karen Lynch at the company’s Feb. 16 earnings call said Aetna will rejoin the Affordable Care Act exchange markets in January 2022. Aetna originally exited the exchanges in the 2018 plan year, citin...
Datapoint: Libtayo Scores Second Skin Cancer Nod
The FDA last week approved Regeneron Pharmaceuticals, Inc. and Sanofi’s Libtayo for the treatment of advanced basal cell carcinoma (BCC) that has not responded to previous treatment in some patients. The anti-PD...
Datapoint: FDA Approves TG Therapeutics’ Ukoniq
The FDA on Feb. 5 granted accelerated approval to TG Therapeutics’ Ukoniq for the treatment of relapsed or refractory marginal zone lymphoma that has not responded to previous treatments. Ukoniq’s trial data...
Datapoint: Oscar Files for IPO
Insurance startup Oscar Health, Inc. on Feb. 5 filed a registration statement with the Securities and Exchange Commission — the next step in its proposed initial public offering. The insurer said it plans to use...
Datapoint: FDA Approves Merck’s Tepmetko for NSCLC Mutation
The FDA last week approved Merck KGaA’s Tepmetko for the treatment of non-small cell lung cancer with MET exon 14 skipping mutations, an aggressive form of the disease which affects between 3% and 4% of NSCLC ...
Datapoint: FDA Approves Bristol Myers Squibb’s Breyanzi
After a series of regulatory and manufacturing delays, the FDA last week approved Bristol Myers Squibb’s CAR-T drug Breyanzi for the treatment of large B-cell lymphoma in patients who have not responded to or re...
Datapoint: Anthem to Acquire InnovaCare’s Medicare Advantage, Medicaid Plans
Anthem, Inc. last week said it entered a deal to acquire InnovaCare Health’s MMM Holdings, the largest Medicare Advantage organization in Puerto Rico. InnovaCare currently enrolls 262,654 Medicare Advantage and ...